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Abstract 
 
Microglia are activated after spinal cord injury (SCI), but their phagocytic mechanisms and link to 
neuroprotection remain incompletely characterised. Docosahexaenoic acid (DHA) has been shown 
to have significant neuroprotective effects after hemisection and compression SCI, and can directly 
affect microglia in these injury models. In rodent contusion SCI, we demonstrate that DHA (500 
nmol/kg) administered acutely post-injury confers neuroprotection and enhances locomotor 
recovery, and also exerts a complex modulation of the microglial response to injury. In rodents, at 
7 days after SCI, the level of phagocytosed myelin within Iba1-positive or P2Y12-positive cells 
was significantly lower after DHA treatment, and this occurred in parallel with an increase in 
intracellular miR-124 expression. Furthermore, intraspinal administration of a miR-124 inhibitor 
significantly reduced the DHA–induced decrease in myelin phagocytosis in mice at 7 days post 
SCI. In rat spinal primary microglia cultures, DHA reduced the phagocytic response to myelin, 
which was associated with an increase in miR-124, but not miR-155. A similar response was 
observed in a microglia cell line (BV2) treated with DHA, and the effect was blocked by a miR-
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124 inhibitor. Furthermore, the phagocytic response of BV2 cells to stressed neurones was also 
reduced in the presence of DHA. In peripheral monocyte-derived macrophages, the expression of 
the M1, but not the M0 or M2 phenotype, was reduced by DHA, but the phagocytic activation was 
not altered. These findings show that DHA induces neuroprotection in contusion injury. 
Furthermore, the improved outcome is via a miR-124-dependent reduction in the phagocytic 
response of microglia. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Spinal cord injury (SCI) is a significant cause of disability worldwide, affecting approximately 
130,000 people annually (1). Despite extensive research, there is still no effective treatment and 
the various cascades of secondary pathology post-injury are poorly understood. SCI is associated 
with a strong inflammatory response, and microglia, resident central nervous system (CNS) 
immune cells, become activated immediately after injury (2, 3). Activated microglia take on an 
4 
 
amoeboid-like morphology that facilitates their migration to the site of the injury, where they 
release a range of cytotoxic mediators (4, 5). Although activated microglia have many similarities 
with monocyte-derived macrophages, they also have differences at the genetic and phenotypic 
levels (6). Furthermore, microglia have been shown to induce a form of primary phagocytosis, 
termed phagoptosis, of stressed but viable neuronal cells (7-9).  However, microglia are also 
known to act as sources of anti-inflammatory mediators and neurotrophic factors, aiding CNS 
repair (10, 11). Microglia initiate both innate and adaptive immune cell responses post-SCI via 
pro-inflammatory cytokine release and major histocompatibility complex (MHC) II antigen 
expression (5, 12). Therefore, microglia exhibit a wide range of functions, which can be neurotoxic 
or neuroprotective. 
 
A robust and protracted macrophage response accompanies microglial activation after SCI. Whilst 
acute depletion or inhibition of CNS macrophages is neuroprotective (13, 14), augmentation of 
this immune cell response can also, paradoxically, lead to CNS repair (15, 16). These divergent 
effects of activated microglia/macrophages might be explained by the induction of functionally 
separate phenotypes, such as the classically activated (M1) and alternatively activated (M2) 
macrophage responses (3, 6).  M1 macrophages produce high levels of pro-inflammatory cytokines 
and oxidative metabolites that are essential for host defence, but can also cause significant 
bystander damage (17, 18). On the other hand, the presence of interleukin (IL) IL-4 or IL-13 
promotes the differentiation of M2 macrophages, which are responsible for several neuroprotective 
and reparative functions (19, 20). It is now well-documented that in the early phases of SCI, 
activated macrophages may acquire a short-lived M2 polarised phenotype, identified by the cell 
marker arginase-1 (arg-1), whereas chronic spinal cord inflammation is characterised by a strong 
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and persistent M1 polarised phenotype, identified by the presence of inducible nitric oxide-2 
(iNOS-2) (21). Therefore, macrophage activity may exacerbate secondary injury or promote tissue 
repair post-SCI, depending on which subpopulation predominates, at different times after the 
initial injury.  
The neuroprotective and macrophage/microglia modulatory effects of docosahexaenoic acid 
(DHA), and other closely related omega-3 polyunsaturated fatty acids such as eicosapentaenoic 
acid (EPA), have been well documented in compression and hemisection SCI (22-27). Although 
the exact pharmacological targets of omega-3 PUFAs driving their neuroprotective effects in SCI 
remain elusive, a range of beneficial effects have been reported after their acute administration 
post-injury in models of compression and hemisection injury, including decreased axonal and 
myelin damage, increased neuronal and oligodendrocyte survival, reduced lipid peroxidation and 
COX-2 activation, and improved locomotor recovery (22, 24, 25, 27-29). However, contusion 
injury represents a pathophysiologically different type of neurotrauma, and may better reflect 
human SCI than hemisection or compression injuries (30). We have recently shown, using in vivo 
positron emission tomography imaging in a rat contusion SCI model, that DHA can alter the levels 
of the translocator protein (TSPO), an inflammatory marker which is up-regulated in glia after 
injury (31). 
 
In this study, we show that acute DHA treatment after injury promotes sustained locomotor 
recovery following spinal cord contusion injury in both rats and mice. This was accompanied by 
increased microglia/macrophage levels, but a reduced myelin phagocytosis, in parallel with an 
increase in microglial microRNA (miR)-124 expression. In vitro, DHA treatment reduces myelin 
phagocytosis in primary adult rat spinal microglia cultures and in the murine microglial cell line 
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BV-2. This phagocytic response appears to involve miR-124. The reduction in phagocytosis 
induced by DHA occurs  in parallel with the neuroprotective effects, thus providing a mechanism 
that may be responsible for the beneficial effects of this fatty acid in contusion SCI. 
 
Results 
 
DHA improves open field locomotor scores in rodent spinal cord contusion injury 
To assess the degree of motor functional loss and subsequent recovery in DHA-treated animals, 
the BBB and BMS open field locomotor rating scores were used to quantify recovery of hind limb 
function following contusion SCI in rats and mice, respectively. Using the scoring parameters 
mentioned in the methods section, both rats and mice showed complete paralysis of both hind 
limbs immediately following contusion SCI (Figure 1A-B). The injury paradigm used for rat SCI 
induced paralysis for only 1 day post-injury (BBB score of 0.6 for vehicle vs. 1.2 for DHA at 1 
day post injury), indicating a moderate spinal contusion (Figure 1A). In the DHA-treated mice, a 
total paralysis (BMS score of 0) was observed for 3 days, whereas vehicle-treated mice were 
paralysed for 5 days post-injury, indicating a severe spinal contusion (Figure 1B). Although 
previous dose studies from our laboratory have shown that 250 nmol/kg DHA exerts significant 
neuroprotective effects in lateral hemisection and compression SCI in rats (22, 25, 32), 500 
nmol/kg compared to 250 nmol/kg DHA exerted a more effective neuroprotection in compression-
injured mice (24). Furthermore, preliminary studies in contusion injury in rats did not show 
significant differences in neuroprotection between 250 and 500 nmol/kg (data not shown). 
Therefore, to maintain similarity in the DHA dose between the rat and mouse contusion injury 
model, the higher DHA dose was chosen in this study, for both species. Intravenous administration 
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of DHA (500 nmol/kg) 30 minutes post-contusion SCI did not induce significantly different BBB 
scores in DHA- vs. vehicle-treated rats on days 0-4 post-contusion. However, significant 
improvement in locomotor recovery was observed from days 5 and 11 onwards, in rat and mouse 
models, respectively (Figure 1A-B). The enhanced locomotor recovery in DHA-treated rats and 
mice remained significant for up to 28 and 35 days post-contusion, respectively (Figure 1A-B). 
These data indicate that a single bolus injection of DHA (500 nmol/kg) can improve locomotor 
function during the early phase of recovery (7 days), with benefits sustained into the later phases 
of recovery (28 and 35 days), after moderate and severe contusion SCI in rodents. 
 
DHA induces neuroprotection in rodent spinal cord contusion injury 
The administration of DHA led to significantly improved neuronal survival on days 7 and 28 post-
contusion injury in rats, as demonstrated by the number of neurons immunostained for the neuronal 
marker NeuN, around the injury epicentre (Figure 2A-J). In particular, significant neuroprotection 
in DHA-treated compared to the vehicle-treated rats was observed in the regions rostral and caudal 
to the epicentre at day 7 post-injury (Figure 2E-G), and regions caudal to the epicentre at day 28 
post-injury (Figure 2H-J). Furthermore, significant neuronal survival was observed in DHA-
treated mice, in the region rostral and caudal to the injury epicentre of the intermediate plane at 35 
days post contusion, when compared to the vehicle-treated group (Figure 2K-S). These results 
show that DHA can protect against neuronal loss after a moderate or severe contusion of the cord.   
 
DHA modulates microglia/macrophage activity in rodent spinal cord contusion injury 
After SCI, there is an increase in activated microglia and the macrophage activation at the injury 
site (21, 22). In the present study, at 7 days post-contusion, DHA-treated rats displayed a small but 
significant increase in ED1 (a marker of activated microglia and monocyte-derived macrophages) 
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expression at 4 mm caudal to the epicentre when compared to control animals (Figure 3A-C). 
Immunostaining for Iba1, a marker that labels activated and non-activated microglia and 
macrophages, was also carried out. At 7 days post-contusion there was also a significant increase 
in Iba1-positive cells at the epicentre, and in regions rostral and caudal to the epicentre, in the 
DHA-treated group compared to vehicle-treated rats (Figure 3D-F). Interestingly, there was also 
an overall increase in the number of Iba1-positive cells in the white matter of mice at 35 days post 
severe spinal contusion injury after DHA-treatment, compared to the vehicle-treated group (Figure 
3H-K, L). However, in the gray matter, the number of Iba1-positive cells was significantly reduced 
in the DHA-treated versus the vehicle-treated group (Figure 3M). However, at 28 days post 
moderate spinal contusion in rat, there was no significant difference in Iba-1 immunostaining 
between the two groups (Figure 3G). Furthermore, there was no significant difference when the 
gray and white matter data was combined, in the mouse contusion study (Figure 3N). These results 
demonstrate that DHA can modulate microglia/macrophages in both the white and gray matter 
caudal and rostral to the injury site after moderate-severe contusion. 
 
DHA enhances both M1 and M2 microglia/macrophage phenotypes in spinal cord contusion 
injury 
In order to further characterize the role of DHA in the modulation of activated 
microglia/macrophages after contusion of the cord, an additional analysis of 
microglia/macrophages using the CD16/32 and arginase-1 antibodies was carried out in mice and 
rats, at early or later stages of the SCI, to identify the two major subtypes of activated 
microglia/macrophage phenotype, namely M1 and M2.  
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As immunostaining with CD16/32 and arginase-1 antibodies on rat contused spinal cord sections 
was unsuccessful, these antibodies were instead used for Western blotting on freshly dissected 
tissue obtained from separate groups of animals. To fully appreciate the acute effects of DHA 
along the entire rostro-caudal spinal cord axis, the expression of CD16/32 and arginase-1 was 
analysed in sequential 3 mm rostro-caudal segments of contused rat spinal cord at 3 days post-
injury (Figure 4A). Both markers were detected in the contused tissue, and a significant increase 
in both CD 16/32 and arginase-1 was observed at the injury epicentre (in comparison to III 
tubulin control protein) after DHA treatment (Figure 4B-F).  
Furthermore, to investigate whether an increase in CD16/32 and arginase-1 expression is also 
detected in another model of  SCI, we studied a lateral hemisection model in mice using 
immunohistochemistry. In the lateral hemisection mouse model at 7 day post injury, there was 
limited CD16/32 (M1 phenotype) expression level, but high arginase-1 (M2 phenoptype) 
expression level that was confined to the ipsilateral side of the injury (Suppl. Figure 1). In 
comparison to the vehicle group, at 35 days post-contusion in mice, markers for both phenotypes 
were detected. Treatment with DHA significantly increased the number of CD16/32 
immunopositive cells at the injury epicentre in the gray matter (Figure 4G-I), and immediately 
caudal to the injury epicentre in the white matter (Figure 4J). Similarly, in comparison to the 
vehicle group at 35 days post-contusion in mice, treatment with DHA significantly increased the 
number of arginase-1 immunopositive cells at the injury epicentre and immediately caudal to the 
epicentre in the gray matter (Figure 4K-M), as well as at the injury epicentre within white matter 
(Figure 4N).  These results suggest that DHA is able to enhance the M1 and M2 phenotypes at the 
acute and chronic stages of spinal cord contusion injury, in the two species. 
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DHA reduces the M1 phenotype in peripheral primary murine bone marrow-derived 
macrophages, but not the phagocytic activity 
To characterize the effect of DHA on microglia and monocyte-derived macrophages originating 
in the periphery, we first tested primary murine bone marrow-derived macrophages, which were 
used to investigate the effect of DHA on the peripherally originating macrophage population.  The 
concentration of DHA used was similar to that previously used in other primary cultures studies 
(25). DHA at 1 and 3 μM did not significantly alter the number of non-activated (M0) or M2 
macrophages (Figure 5A-I). However, DHA at 3 μM significantly reduced the number of M1 
macrophages (Figure 5A-H).These results suggest that DHA can significantly reduce the M1 
phenotype, but not the M0 and M2 phenotypes of peripheral monocyte-derived macrophages. In 
an additional experiment, the effect of DHA on the phagocytic activation of M1 or M2 
macrophages was studied. No significant change was observed between the DHA-treated group at 
3 M, compared to the vehicle control group (Figure 5J-R). Therefore, the observed modulatory 
effects of DHA on M1/M2 markers in the spinal cord after injury are unlikely to involve 
peripherally originating macrophages. 
 
DHA increases miR-124 in microglia and reduces phagocytosis of myelin in vivo  
Since microglia have phagocytic activity in the CNS (5, 33), the significant increase in activated 
microglia by DHA could result in increased phagocytosis and improved debris clearance. To test 
this hypothesis, the levels of myelin co-localised within microglia/macrophages were analysed 
using immunohistochemistry. At the injury epicentre level, there was a high level of myelin present 
within Iba1-positive cells of vehicle- and DHA-treated rats, at 7 days post- contusion (Figure 6A-
F). However, to our surprise, the level of myelin present within Iba1-positive cells at 4 and 6 mm 
rostral to the injury epicentre in DHA-treated rats was significantly reduced compared to vehicle-
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treated rats (Figure 6G-M). To further understand how DHA may alter microglial function, we 
studied a particular microRNA, miR-124, which has been shown to have an important association 
with microglia/macrophage activation. Thus, miR-124 has been previously shown to correlate 
inversely with microglia/macrophage activation, as well as inducing the M2 neuroprotective 
phenotype (34, 35).Using the fluorescent in situ hybridisation (FISH) technique, we show that 
there was a significant increase in miR-124 expression in the Iba1-positive microglia/macrophages 
of DHA-treated compared to vehicle-treated SCI animals at 7 days post-injury in contused rats 
(Figure. 7A-G). 
To investigate how these changes are associated with neurological outcome, we studied the 
phagocytosis of myelin in mouse contusion SCI. Recently, the P2RY12 gene (purinergic receptor 
P2Y12) has been found uniquely in microglia and not monocyte-derived macrophages (6, 36, 37). 
Therefore, the co-expression of P2Y12 and myelin-binding protein (MBP) as a myelin marker  was 
analysed in microglial cells in vehicle- and DHA-treated mice, at 7 days post-contusion, and the 
neurological outcome was assessed in parallel (Fig. 8A-K). In the rostral and caudal regions, there 
was a significant reduction in the MBP staining within P2RY12-positive cells, after administration 
of DHA (Fig. 8B-K). These observations in both contused rats and mice suggest that the 
phagocytic property of microglia is reduced by DHA. Furthermore, we also showed a significant 
increase in miR-124 expression in P2Y12 positive microglia of DHA-treated compared to vehicle-
treated SCI mice at 7 days post injury (Fig. 9). Importantly, intraspinal administration of a miR-
124 inhibitor significantly reduced the miR-124 levels (Fig. 9) and prevented the reduced 
phagocytic response of microglia, and this was parallel  with the compromised neurological 
recovery (Figure 8). This suggests that the reduced phagocytic activity of microglia is associated 
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with an increase in miR-124 expression within microglia. Interfering with this modulation of miR-
124 activity appears to have a major impact on the beneficial effects of DHA. 
 
 
DHA acts via miR-124 to reduce microglial phagocytosis of myelin in cultures  
To further provide evidence that DHA can reduce the phagocytic response of microglia, DHA was 
added to primary adult spinal microglia cultures which were exposed to myelin stained with the 
fluorescence dye DiI, to observe phagocytic effects. In the presence of DHA (1 and 3 µM), there 
was a general reduction in DiI-labelled myelin detected within adult primary microglia, with a 
significant reduction observed at 1 µM DHA at 24 hours after incubation, as detected using 
fluorescent microscopy (Figure 10A-G). To determine if DHA directly influences microglia via 
miR-124, the microglial miR-124 expression was analysed using quantitative RT-PCR. MiR-124 
expression was significantly increased in the DHA-treated primary adult microglia cultures, 
specifically at 1 µM, when compared to the control group (Figure 10H). To test whether the effect 
seen is specific to miR-124, another microRNA that modulates the microglia immune response, 
miR-155, was also investigated (38). Interestingly, no significant difference was observed in miR-
155 expression at any of the DHA concentrations studied (Figure 10I). To further test the effect of 
DHA on the phagocytic ability of microglia, the commonly used BV2 microglial cells were also 
studied. DHA at 3 M caused a significant reduction in the amount of DiI-myelin present within 
the BV2 cells (Figure 10J-K, M). In addition, inhibition of miR-124 using a miR-124 inhibitor (3 
pmol/ml) was able to significantly reverse the ability of DHA to suppress myelin phagocytosis by 
BV2 cells (Figure 10L-M). These results further suggest that the phagocytic property of microglia 
is reduced by DHA, and this is dependent on changes in miR-124.  
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DHA reduces phagoptosis of UV-stressed neurones by microglia 
In recent studies, activated microglia have been shown to phagocytose stressed but viable neurons, 
alongside lesion debris and dead cells (9). Therefore, DHA may confer neuroprotection by 
preventing phagoptosis (the phagocytosis of stressed but viable cells), thus providing time for 
neurons to self-repair or recover. To test this hypothesis, UV-stressed PC12 neurons were 
incubated with DHA-treated BV2 microglial cells. PC12 neurons were exposed to 200 mJ/cm2 and 
then left for 16 h, which caused a significant increase in apoptosis as detected by labelling for 
phosphatidylserine (using Annexin V; Suppl. Figure 2A-C). UV-stressed PC12 cells were then 
labelled with TMRE (red) and Hoechst (blue), a live mitochondria marker and nucleus stain, 
respectively. The use of TMRE and Hoechst enabled the visualisation of live stressed PC12 cells 
(red and blue). Of note, when live stressed (apoptotic) PC12 cells come into contact with BV2 
microglia, the Hoechst (blue) staining remains, whereas the red colour from TMRE is no longer 
present. In addition, the BV2 microglia were labelled with CMFDA (green) when co-cultured with 
neurons.  
 
Using live imaging microscopy, we show that BV2 microglia induce a TMRE loss (mean ± 
S.E.M.) of 63.7 ± 2.9 % in UV-stressed PC12 cells (Figure 11A & C). However, when BV2 
microglia were pre-treated with DHA, there was a marked and significant reduction in the number 
of cells with TMRE loss, of 32.8 ± 11.5 and 28.5 ± 9.2, at the 1 or 3 M DHA concentrations, 
respectively (Figure 11A-C).These results suggest that DHA reduces the phagoptotic effect of 
microglia, thus providing one of the potential mechanisms enhancing the survival of viable 
stressed neurons. 
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Discussion 
 
The present study demonstrates that DHA promotes significant functional improvement as well as 
neuroprotection after spinal cord trauma in two rodent contusion injury models – and this 
consolidates the neuroprotective profile shown for this fatty acid in hemisection and compression 
models, thus enhancing the clinical translation potential. The neuroprotective benefits of DHA are 
associated with an increase in activated microglia/macrophages at the injury epicentre, both for 
the M1 and M2 phenotype. In a model of peripheral monocyte-derived macrophages, DHA 
promoted only a reduction in the M1 phenotype of bone marrow-derived macrophages and had no 
significant effect on either the M0 or M2 phenotypes. In vivo, DHA promoted an increase in 
microglial miR-124 expression, with reduced phagocytosis of myelin at 7 days post contusion. In 
vitro, DHA promoted a reduction in the phagocytosis of myelin by two types of microglial cell 
cultures. Furthermore, DHA prevented the microglial phagoptosis of stressed but viable neurons. 
The reduction in the myelin phagocytic response in vitro was linked to a DHA-induced increase 
in miR-124, and not miR-155. 
 
DHA improves neurological outcome and protects neurones after contusion SCI 
A number of studies have examined the neuroprotective effects of omega-3 fatty acids following 
SCI induced by hemisection or compression (22, 24, 25, 27, 29, 39). So far, several favourable 
effects of DHA administration (behavioural and histological) post-injury have been described, 
including decreased axonal and myelin damage, increased neuronal and oligodendrocyte survival, 
decreased macrophage/microglia cell recruitment and reduced lipid peroxidation and COX-2 
activation (22, 24, 25, 27, 29, 39, 40). The results of the current study show that DHA treatment 
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30 minutes post-injury significantly improves locomotor function in rodents, both in the early (7 
days) and late phase (35 days) of spinal cord contusion injury. As transection or hemisection 
injuries are rarely seen in human spinal cord trauma, contusion injuries are a more relevant model 
for investigating the potential of various new treatments for human SCI (30, 41, 42). We have 
previously demonstrated that DHA can improve neurological outcomes in contusion-injured rats 
in the first week after injury (31), and we further demonstrate in the present study that significant 
locomotor improvement continues to 28 and 35 days post-injury in rats and mice, respectively, 
therefore the beneficial effect is robust and persistent. In accordance with improved motor 
recovery, increased neuronal survival was also observed at 7 and 28 days post-contusion in DHA-
treated rats. Furthermore, DHA-treated mice also showed significantly improved neuronal 
survival when compared to vehicle-treated animals at 35 days post contusion. Thus, the 
demonstration of significant locomotor recovery alongside improved neuronal survival after 
contusion injury supports a considerable neuroprotective role for DHA, acutely administered 
post-SCI. 
 
However, the observations reported so far in SCI have not differentiated the impact of this fatty 
acid on different microglia/macrophage cell populations and phenotypes, and this was a major 
focus of the present study. First, we showed that DHA treatment significantly increased Iba-1 
expression levels during the early phase (7 days) of contusion SCI in rats. Overall, Iba-1 
immunopositive microglia/macrophage cell counts were either unaffected or decreased by DHA 
treatment during the late phase of contusion SCI in rats and mice (28 and 35 days). As activated 
microglia/macrophages have been shown to acquire an alternative M2 polarised phenotype 
(identified by CD206+/CD204+/arg-1+) during the early phases of SCI (3, 21), by enhancing the 
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M2 response DHA could provide additional neuroprotective support. Later on, as 
microglia/macrophages are said to drift towards a predominantly  M1 polarised phenotype 
(identified by CD16+/CD32+/CD86+/iNOS-1+) during the post-acute and chronic phases of SCI (3, 
21), DHA treatment may also potentially dampen harmful cell phenotypes over time.  
 
Pre-stimulated macrophages implanted into damaged rodent spinal cords greatly improve 
functional recovery after injury (15, 43). Taking this complexity into account, DHA treatment has 
the potential to modulate microglia/macrophage activity in both the early and late phases of SCI, 
in a manner which may simultaneously enhance beneficial functions and limit deleterious effects 
of microglia/macrophages. Importantly, we did not find evidence to support the claim that DHA 
is able to boost only the M2 microglia/macrophage populations after SCI. In fact, our data show 
an increase in the M1 (CD16+/CD32+) as well as the M2 (Arg-1+) population, via Western blot at 
3 days and tissue cell counts at 35 days, in mice (Figure 4), strongly suggesting that DHA can 
augment both M1 and M2 cell phenotypes post- contusion SCI. Although these results did not 
match our initial hypothesis, we believe two plausible interpretations exist. Firstly, increased M1 
populations during the late phase of SCI could represent an earlier DHA-induced expansion of M2 
phenotypes, which have subsequently acquired the M1 profile over time. Secondly, the 
enhancement of M1 microglia/macrophages by DHA-treatment may not necessarily represent per 
se the acquisition of a neurotoxic phenotype. For example, DHA-treatment of lipopolysaccharide-
activated microglia has been shown to inhibit pro-inflammatory mediator release (i.e. NO, iNOS, 
TNF-α and IL-6) without inducing an alternative anti-inflammatory M2 phenotype (i.e. Arg-1, IL-
10) (44). Our results imply that DHA is capable of inducing region-specific M1 responses within 
both gray and white matter, which might have separate neuroprotective roles. Furthermore, despite 
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its utility as a working model to study macrophage heterogeneity in vivo, the M1/M2 classification 
of activated microglia/macrophages is an over-simplification, with at least one additional 
macrophage activation state, as well as several M2 sub-classifications believed to exist (3, 21, 45, 
46). For this reason, it can be assumed that more than one M1 subtype may be present after injury, 
which, contrary to current views, may serve important neuroprotective functions. 
 
DHA reduces microglial phagocytosis of myelin debris 
It is thought that phagocytosis of myelin debris is crucial for lesion clearance and subsequent 
axonal repair (47). Recently, Chen and colleagues showed that DHA and EPA can enhance myelin 
phagocytosis in vitro (48).  To our surprise, in our study DHA did not enhance phagocytosis of 
myelin debris in primary adult microglia cultures; reduced DiI-labelled myelin clearance was 
observed at 1 µM DHA after 24 hours of incubation (Figure 8). Furthermore, our in vivo data also 
confirm that DHA treatment causes a reduced phagocytosis of myelin at 7 days after injury (Figure 
6). The differences in in vitro results may reflect the fact that Chen and colleagues used primary 
microglia from neonatal brain and a high DHA concentration (20-80 M). In contrast with their 
work, we used primary microglia from the spinal cord of adult animals (which is directly relevant 
to the microglia population studied in the post-contusion tissue), and in addition a microglia cell 
line (BV2 cells), and a DHA concentration that was between 1-3 M, and thus more relevant 
physiologically. In fact, myelin phagocytosis has been shown to induce the production of many 
pro-inflammatory mediators (i.e. ROS, TNF-α. IL-6 and IL-1), causing significant bystander 
damage if left unregulated (49-52). As phagocytosis of myelin has been shown to be neurotoxic in 
nature and elicit a M1 macrophage response (53), DHA may serve to dampen excessive myelin 
removal, protecting against further bystander damage. Interestingly, a pro-regenerative treatment 
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induced by lentiviral vector-driven expression of chondroitinase ABC in contusion SCI, has been 
shown to lead to an amplification of a phagocytic microglia/macrophage phenotype at 3 days post-
injury (Bartus et al., 2014), whereas at 2 weeks after injury the opposite effect was seen.  
Furthermore, in the same study, a significant amplification of the increase in CD206-expressing 
microglia triggered by injury, was also seen at 2 weeks after treatment. 
 
When co-cultured with neurons, microglial cells were able to selectively phagocytose and remove 
dying cells, whilst leaving healthy neurons intact (54). We speculate that the phagocytosis of dying 
cells by microglia (and possibly also by macrophages) may explain the increased Iba-1 
immunopositive expression levels observed at 7 days post-contusion injury. Later on, increases in 
white matter Iba-1 expression levels and CD16/32 and arginase-1 immunopositive cell counts 
(epicentre to 1 mm caudal) at 35 days, suggest that DHA may support remyelination in these areas 
and reduce excessive and unnecessary myelin phagocytosis. Our interpretation is supported by 
studies on demyelination/remyelination processes (55) which did not find evidence supporting the 
idea that M1 microglial phenotypes drive demyelination whilst M2 populations enhance 
remyelination. In fact, the microglia phenotype present during demyelination persists over time 
post injury, suggesting a gradual and more subtle switch in microglia functions that support 
remyelination (55). Furthermore, both M1- and M2-phenotype markers were shown to be up-
regulated during periods of demyelination and remyelination (55). Microglial cells were also 
shown to support myelination by providing important trophic support to oligodendrocyte 
progenitor cells (55). Similarly, concurrent microglial iNOS expression showed moderately 
protective effects against demyelination (55). Therefore, DHA treatment may be able to prevent 
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microglia/macrophage cell death after injury, thus enabling the acquisition of more subtle 
neuroprotective roles of these cells over time.  
 
 
DHA enhances microglial miRNA-124 expression 
To understand how DHA may directly influence microglial cells, the effect of DHA on miR-124 
was analysed using FISH and quantitative RT-PCR techniques. Our results indicate that DHA is 
able to significantly increase microglial miR-124 expression in the injured spinal cord and primary 
adult microglial culture (Figure 7 & 9). In un-injured spinal cord, miR-124 in microglia was not 
detectable (data not shown). As miR-124 has been shown to correlate inversely with 
microglia/macrophage activation, as well as inducing M2 phenotypic changes after CNS trauma 
(34, 35), our data suggest that DHA is capable of modulating microglial activity after SCI via the 
enhancement of miR-124 expression. A very important observation in this study is that the early 
interference with the activity of miR-124, compromises motor improvement after DHA, 
suggesting that the microglia modulation is an important aspect of the neuroprotective effect of 
the fatty acid. 
 
Long-chain omega-3 fatty acids such as DHA have a multitude of molecular targets that could 
drive the effect on miRNA and on microglia activity (56, 57), such as the peroxisome proliferator-
activated receptors and retinoid receptors, or TREK-1 channels - targets which are all possible 
candidates for a modulation of microglia (58, 59), and this aspect remains to be characterised in 
future studies.  
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Conclusion 
The results of the present study show that DHA can act directly on microglia and reduce their 
phagocytic activity. DHA induces neuroprotection after moderate or severe contusion SCI in 
rodents and a markedly improved neurological outcome. Interestingly, DHA seems to be able to 
enhance early gray matter microglia/macrophage (Iba-1+) cell populations (7 days) when 
compared to control animals, which then remained unchanged or decreased in the late phase (28 
and 35 days) after SCI. Therefore, DHA is able to augment early microglia/macrophage responses 
after severe contusion. DHA is shown to enhance gray and white matter M1 (CD16/32+) responses 
in mouse contused cords at 35 days.  Increased M1 populations may represent an earlier DHA-
induced expansion of M2 phenotypes that have subsequently acquired M1 reactivity over time, or 
the acquisition of a non-reactive M1 phenotype, enabling improved locomotor recovery. 
Furthermore, increased white matter CD16/32+ microglia/macrophage populations over time may 
enhance remyelination and support oligodendrocyte cells in this process. DHA-treatment reduces 
myelin phagocytosis in vitro (a process linked to phagoptosis) and enhances miR-124 expression 
(an important microRNA associated with the acquisition of M2 phenotypes), in vivo and in vitro. 
Therefore, our data demonstrates that DHA is associated with a complex modulation of the 
microglia/macrophage response, which occurs in parallel with a significant neuroprotective effect 
after contusion SCI in rodents.  
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Materials and Methods 
 
In vivo study 
Spinal cord contusion injury  
All animal surgery was carried out under the UK Home Office Scientific Procedures Act (1986) 
and EU directive 2010/63/EU. The ARRIVE guidelines were followed for this study. Female 
Sprague-Dawley rats (230 - 250 g) were anaesthetized intraperitoneally with a mixture of 
medetomidine (Domitor, 0.5 mg/kg) and ketamine (Ketaset, 60 mg/kg), after which they received 
a contusion injury at spinal thoracic level T10/11 level using the PinPoint controlled cortical 
impactor (velocity; 1.5 m/s, dwell time; 100 ms, penetration depth; 1.7 mm, tip diameter; 2 mm) 
(Hatteras Instruments, USA). Adult female C57BL6 mice (age 12 weeks old) were anesthetised 
intraperitoneally with a mixture of medetomidine (0.5 mg/kg) and ketamine (75 mg/kg) before 
receiving a spinal thoracic level T10/11 contusion injury using the PinPoint controlled cortical 
impactor (velocity; 0.7 m/s, dwell time; 85 ms, penetration depth; 0.8 mm, tip diameter; 1.5 mm). 
All animals underwent daily weight monitoring, twice daily buprenorphine treatment and manual 
bladder expression until it was no longer necessary.  
 
DHA treatment  
SCI surgery was performed in two groups of animals receiving either an intravenous (i.v.) injection 
of vehicle (saline containing 0.2 % ethanol) or DHA (free fatty acid; 500 nmol/kg) (Sigma-Aldrich, 
D2534) 30 minutes post-injury.  All i.v. injections were administered via the tail vein in a volume 
of 1 ml/kg. Animal surgeons were blinded to treatment type. Sprague-Dawley rats were sacrificed 
at 7 and 28 days after injury, whereas C57BL6 mice were sacrificed at 35 days after injury.  
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Intraspinal miR-124 inhibitor and intravenous DHA injection 
In a separate study in mice with contusion SCI, animals received 0.5 l intraspinal injections in 
both the caudal and rostral region of the contused spinal cord using a glass micro glass needle via 
a microinfusion pump, as previously described (27, 60). Each mouse received either 25 pmol of 
miR-124 miRCURY LNA miRNA inhibitor or negative control A, which acts as a miRCURY 
LNA miRNA inhibitor control (Exiqon, Y104101112, Y100199006) mixed with Lipofectamine 
2000 (Invitrogen, 2 l in 50 l PBS) as the transfection reagent. Thirty minutes post contusion 
injury, DHA or vehicle were intravenously administered as described above. 
 
Behavioural analysis  
The Basso-Beattie-Bresnahan (BBB) open field locomotor rating score (0-21) and Basso Mouse 
Scale (BMS) (0-9) were used to rate hind limb movement following contusion (61, 62). BBB and 
BMS scoring was conducted in an open field (4 minute sessions) on days 1-7, 14 and 28 post-
injury (Sprague-Dawley rats), as well as every day for the first week, then every other day until 35 
days post-injury (C57BL/6 mice).  All tests were performed and analysed by individuals who were 
blinded to the treatment type.  
 
Immunohistochemistry  
Animals were perfused with saline followed by 4% paraformaldehyde, for histology. Spinal cord 
segments containing the lesion site including the rostral and caudal regions were dissected out and 
embedded in OCT compound. Serial horizontal cryostat sections (rat; 20 m, mice; 15 µm) were 
collected across SuperFrost Plus microscopes slides and processed for immunohistochemistry. 
Each slide contained a selection of dorsal, intermediate and ventral cord sections. Sections 
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underwent 3 x 5 min 10 mM phosphate buffer saline (PBS) washes before incubation in 0.3 % 
hydrogen peroxide in PBS for 10 min to remove endogenous peroxidase.  For all washes, sections 
were gently agitated on a shaker. For immunohistochemical labelling, sections were blocked with 
10 % normal goat serum (containing 10 mM PBS, Triton X-100 and sodium azide) for 1 hour 
before incubation with the primary antibody. Antibodies used were: ionised calcium binding 
adaptor molecule 1 (Iba-1, 1:1000, Wako 019-19741), which labels activated and non-activated 
microglia/macrophages; P2Y12 (1:200, Cambridge Bioscience, ANA55043A), which labels 
microglia; CD16/32 (1:500, BD Pharmingen 553141), a specific marker of M1 activated 
microglia/macrophages; Arginase-1 (1:250, Santa Cruz, sc-18354), a specific marker of M2 
activated microglia/macrophages, NeuN (1:1000, Chemicon MAB377), for neuronal cells; myelin 
basic protein (MBP, 1:500, Abcam ab62631) for the most abundant protein component of myelin. 
Sections were incubated with primary antibody overnight in a humidified chamber at room 
temperature.  The following day, sections underwent 3 x 5 min PBS washes before incubation with 
secondary Alexa Fluor antibodies (Invitrogen®). Tissue sections were incubated in a humidified 
chamber for 2 hours at 4°C. After application of secondary antibodies, sections underwent a further 
3 x 5 min PBS washes before mounting with Vectashield and DAPI.  
 
Fluorescence In situ hybridisation (FISH) and Immunohistochemistry 
The FISH procedure was carried out using the 5’-biotin labelled rno-miR-124 microRNA in situ 
probe (miRCURY LNA™ detection probe, Cat. No. 614870-370, Exiqon) according to 
manufacturer’s instructions similarly to previously published (63). Briefly, horizontal rat spinal 
cord sections containing the injury site were washed 3 x 5 min DEPC-treated 10 mM PBS then 
dehydrated through a graded series of alcohol and air-dried. Sections were incubated overnight 
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with 40 nM miR-124 microRNA probe diluted with microRNA in situ hybridisation buffer (Cat 
No. 90004, Exiqon) at 59 oC. RNase A-treated spinal cord sections were used as a negative FISH 
control. Next day, slides were washed in a series of pre-heated DEPC-saline-sodium citrate (SSC) 
solutions at 59oC for 5 min each. After further washes in 0.2 x SSC and 1 x PBS at room 
temperature for 5 min each, slides were incubated with 0.3% hydrogen peroxide for 30 min. 
Thereafter, the biotin signal on the miR-124 microRNA was amplified using the Avidin-Biotin 
complex (Vectastain ABC Elite Kit, Vector Labs) and biotinyl tyramide (1:75, NEN Life Science 
Products), and visualised with ExtrAvidin®-FITC (1:400, Sigma). After the FISH procedure, the 
sections were incubated with Iba1 antibody overnight followed by secondary Alexa Fluor 594 for 
2 h, and coverslipped with Vectashield and DAPI as mentioned above.   
 
Image Analysis 
Spinal cord sections with NeuN, Iba-1, CD16/32, Arg-1 and MBP immunolabelling, and miR-124 
FISH staining were viewed on a Leica epifluorescence microscope. Images were obtained using a 
20x objective lens. In rat spinal cord tissue sections, two adjacent regions of interest (ROI) were 
selected for analysis at the contusion epicentre as well as regions rostral and caudal to the injury 
epicenter (2, 4 and 6 mm rostral and caudal). Images of each ROI were captured at 3 different 
depths (dorsal, central and ventral sections of the cord).  For rat contused cords, the area occupied 
by Iba-1 immunopositive cells was measured using the MetaMorph image analysis programme. 
Percentage threshold area (area occupied by immunopositive cells) was calculated via the use of 
intensity thresholding. Co-localisation of Iba1+ cells with MBP or miR-124 was analysed using 
ImageJ. For mice contused cords, immunopositive cell number and size were recorded every 1 
mm in the rostrocaudal plane and at 3 different depths, using the Image J software programme. 
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Cell counts and cell size were averaged per ROI and then per whole cord to give overall values for 
the lesion epicentre as well as ROI rostrally and caudally. For the localisation of myelin within 
microglia, a customised macro was used to identify the co- localisation of myelin within Iba1+ 
cells in the white matter from 7d contused rat spinal cord. The difference in some of the image 
analysis used between different experiments was due to the studies being carried out 
simultaneously and independently by different members of the research group. For the 
identification of myelin within P2Y12+ microglial cells in the spinal cord of 7d contused mice, a 
customised ImageJ macro was used. A 500 m x 500 m square was placed within the ROI of 
each side of the spinal cord. The macro enabled all P2Y12+ staining within the ROI of the image 
and all the MBP staining within the ROI of the same image to be identified. Thereafter, the images 
were superimposed and only MBP staining present within the P2Y12+ cells was considered for 
the quantification. The MBP staining value for each ROI was the average MBP staining per 
P2Y12+ microglial cell. 
 
Western blot analysis 
The method used has been previously described (64). Briefly, adult rats with spinal cord contusion 
injury were either treated with DHA or vehicle at 30 min post contusion as mentioned above. Three 
days post injury, the animals were sacrificed and the spinal cord was  quickly removed onto dry 
ice and then stored at -80oC until further processing. The spinal cord was dissected into 3 mm thick 
cross sections, with the centre of the injury site as the epicentre. A further 2 and 3 segments were 
also removed caudal and rostral to the epicentre, respectively. The protein from each cord segment 
was harvested in 1 ml ice-cold lysis buffer (20 mM HEPES pH 7.4, 100 nM NaCl, 100 mM NaF, 
1 mM Na2VO4, 5 mM EDTA, 1% Nonidet P-40 and 1X protease inhibitor cocktail; Roche). The 
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homogenate was rotated for 2 h at 4oC before centrifugation at 13,500 g for 15 min at 4oC. The 
total protein concentration of the supernatant was determined using the bicinchoninic acid protein 
(BCA) assay kit (Pierce). 
Fifteen micrograms of total protein were electrophoresed on 12% acrylamide gel before transfer 
onto Hybond P membranes and incubated overnight at room temperature with rat anti-CD16/32, 
rabbit anti-arginase-1, or mouse anti-III tubulin (control protein). To avoid batch differences, 
each blot contained an animal from each treatment group. 
 
In vitro study 
Bone marrow derived macrophages 
The method used has been previously described (21). Briefly, the tibias and femurs of C57BL/6 
mice were removed and the bone marrow flushed out using RPMI 1640 with 10% fetal bovine 
serum. Cells were triturated 3-5 times and red blood cells lysed in lysis buffer (0.15M NH4Cl, 10 
mM KHCO3, 0.1 mM Na2EDTA; pH7.4). After a single wash in media, cells were cultured in 
RPMI 1640 containing 1% penicillin/streptomycin, 1% HEPES, 0.001% β-mercaptoethanol, 10% 
FBS and 20% supernatant from sL929 cells. After 7-10 days, when the bone marrow cells have 
differentiated into macrophages, the cells were either treated with media alone (termed M0) or 
differentiated into M1 or M2 macrophages. The differentiation into M1 macrophages required 
treatment with LPS (100 ng/ml) and IFN-γ (20 ng/ml). The differentiation into M2 macrophages 
required treatment with IL-4 (20 ng/ml). After 30 min of either control or treatment to differentiate 
into M1 or M2, DHA (1-3 μM) was incubated with the macrophages. Twenty-four hours later, the 
cells were fixed with 4% paraformaldehyde and underwent immunostaining for Iba1, CD16/32 
and DAPI. 
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The number of cells and immunostaining intensity was measured using the Thermo ScientificTM 
ArrayScanTM XTI High Content Analysis Reader. Ten regions of each well with each treatment 
and condition consisting of two wells were analysed. Four independent experiments were carried 
out.  
 
 
Primary adult rat microglia culture 
Primary microglia cultures from adult rat spinal cord were carried out as previously described (65). 
Briefly, adult Wistar rats were deeply anaesthetised with sodium pentobarbital (120 mg/kg, i.p.) 
then perfused with saline to flush away monocytes/macrophages. The spinal cord was dissected 
out and placed into ice-cold Hanks Balanced Salt Solution (HBSS) media. The dura mater and 
spinal roots were removed before cutting longitudinally at 200 µm segments using a McIlwain 
tissue chopper. After digestion in papain followed by dissociation, the cell suspension was passed 
through a 70 μm sieve.  Five l of cell suspension was stained with 5 l DAPI. Using an epi-
fluorescent microscope DAPI immunopositive cells were counted and 40,000 cells were plated 
into each well containing a sterile ethanol-cleaned 13 mm diameter cover slip. After 2 h, un-
attached cells were washed away with DFP media (containing Dulbecco’s modified eagle medium 
(DMEM), 15% heat-inactivated foetal bovine serum (HI-FBS) and penicillin-streptomycin; 100 
IU/ml), and allowed to incubate overnight at 37oC and 5% CO2 and were used the next following 
day for experimental studies. 
For data analysis, Iba-1 and DiI immunopositive cells were counted using the Image J program. 
Ten regions of interest were selected for analysis per well (65). The average amount of DiI within 
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each cell per DHA treatment concentration was analysed. Four independent experiments in each 
treatment group; control (DFP media containing 0.0003% ethanol), 1 and 3 µM DHA were studied.  
 
  
Retroviral immortalised murine (BV2) microglia culture 
The BV2 microglia cell line was cultured as previously described (66). Briefly, BV2 cells were 
cultured in DMEM supplemented with 10 % HI-FBS and penicillin-streptomycin under 37 oC and 
5 % CO2. During experimental studies, the HI-FBS was reduced to 5 %. 
 
Myelin phagocytosis 
Preparation of spinal cord myelin 
Myelin was purified from rat spinal cord tissue by sucrose gradient centrifugation as previously 
described (67, 68). Briefly, the spinal cords were homogenised with a glass-glass homogeniser in 
0.32 M sucrose and then layered onto 0.85 M sucrose. After centrifugation at 75,000 g for 30 min, 
the crude myelin was transferred into 20 volumes of 0.32 M sucrose and centrifuged 13,000 g for 
25 min. The white myelin pellet was resuspended in 25 volumes of sterile water and centrifuged 
at 15,000 g for 25 min. The pure myelin pellet was dissolved in 2.5 mM Tris (pH 7.0) and the 
protein concentration was determined using the Pierce BCA assay.  
 
DiI labelling of myelin 
Labelling of spinal cord myelin with fluorescent dye DiI was carried out as previously described 
(69). Myelin (1 mg/ml) was labelled by incubating with DiI (0.2 mg/ml, Cambridge Bioscience 
Ltd, BT60010) at 37oC for 30 min. After resuspension with 40 volumes of sterile DPBS, the 
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solution was briefly sonicated for 15 s to decrease particle size (70). After centrifugation at 15,000 
g for 5 min, the DiI-labelled myelin was resuspended in 5 % DMEM (1 mg/ml). 
 
Phagocytosis of DiI-myelin 
Microglia or bone marrow-derived macrophages were incubated for 30 min with DiI-labelled 
myelin (50 g) per well before DHA (1-3 µM) was added. After 24 h, the media were removed 
and the cells were either frozen on dry ice for RNA extraction or fixed with 4% paraformaldehyde 
for immunocytochemistry.  
 
Inhibition of DiI-myelin phagocytosis in vitro 
To study the role of DHA on miR-124, 3 pmol/ml miRCURY LNA microRNA inhibitor 
specifically designed for rno-miR-124 (Exiqon, 4104239-001) complexed with the transfection 
reagent Lipofectamine 2000 (Invitrogen) was added an hour before application of DHA, as 
previously described (25). 
 
Phagoptosis of UV stressed neurones 
Neuronal (PC12) cell lines were used to assay the effect of DHA on the phagoptosis of microglia 
BV2 cells similarly to the method previously published (9). 
 
PC12 cells 
PC12 cells were cultured in complete medium (containing DMEM, 5% heat inactivated horse 
serum, 5% HI-FBS and penicillin-streptomycin) at 37oC and 5% CO2. During the experimental 
studies, the PC12 cells were transferred onto collagen (2 mg/ml, Roche Diagnostics, 
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11179179001) covered 9 cm dish HI-FBS and were differentiated into neurons when cultured in 
differentiation medium (containing DMEM, 1% heat-inactivated horse serum, nerve growth factor 
(50 ng/ml, Sigma-Aldrich, N0513), and penicillin-streptomycin).  
 
Live cell imaging 
On the day of the experiment, BV2 and PC12 cells were incubated with the relevant fluorescent 
dyes for 20 min at 37 oC and 5 % CO2, and then thoroughly washed several times with DPBS to 
remove any free dye. BV2 cells were labelled with 5-chloromethylfluorescein diacetate (0.4 M, 
CellTrackerTM green CMFDA, C7025, a green fluorescent dye suited for monitoring cellular 
movement and location). PC12 cells were exposed to 200 mJ/cm2 irradiation using the CX-2000 
UV crosslinker to stress the neuronal cells. The following day, the UV-treated PC12 cells were 
stained with tetramethylrhodamine ethyl ester (25 nM, TMRE, ThermoFisher, T-669, a red 
fluorescence dye that readily labels active mitochondria) and Hoechst 33342 (10 g/ml, 
ThermoFisher, H1399, a blue fluorescence dye that is a cell-permanent nuclear counterstain). 
Sixteen hours after the UV treatment, the PC12 cells were harvested by trypsinisation and added 
onto the DHA-treated BV2 cells. Time-lapse microscopy was conducted on an inverted 
microscope (Zeiss Axiovert 200M) at x20 magnification in improved MEM (ThermoFisher, 
10373-017) without Phenol red, supplemented with 5 % HI-FBS and using the 24 well plate at 37 
oC, 5% CO2 and in a humidity-controlled chamber. Two regions within the well were randomly 
selected and images were time-lapse captured every 9 min for a total of 3 h. 
 
Analysis of time-lapse microscopy 
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The number of contacts made between a BV2 cell (green) and UV-stressed PC12 cells (red with 
blue nuclei) was recorded. After the contact was made, the number of PC12 cells which lost the 
red fluorescence as an indicator of no active mitochondria was also recorded. 
 
UV-induced apoptosis 
To confirm that neuronal PC12 cells were stressed from the UV irradiation protocol, PC12 cells 
plated onto collagen-coated glass coverslips and cultured in differentiation medium were exposed 
to 200 mJ/cm2 irradiation. Sixteen hours after the UV treatment, the PC12 cells were stained using 
Annexin V Alexa Fluor® 488 (ThermoFisher, V13241) according to the manufacturer’s 
instruction for imaging microscopy. 
 
 
 
Immunocytochemistry 
All microglial cultures underwent 3 x 5 min PBS washes before incubation with primary antibodies 
for two hours.  Primary microglia were stained using rabbit anti-Iba1 (1:500 Wako) and BV2 
microglia cell lines were stained with biotinylated Isolectin-B4 (1:200, Vector Labs B-1205) 
before applying secondary antibodies for 45 minutes. After performing 3 further PBS washes, 
microglia cultures on glass cover slips were mounted onto glass slides with DAPI and Fluorsave 
mounting media. The lipophilic dye DiI was used to visualise myelin within microglial cultures, 
which is a red fluorescence dye when viewed with fluorescent microscopy. 
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Quantitative RT-PCR analysis of miRNA 
Total RNA was extracted from primary adult microglia cultures by using the miRVANA™ 
PARIS™ isolation kit (AM1560, Life technologies) similarly to previously published (71). 
Microglial cells from 2 wells per treatment were pooled together. Total RNA was quantified using 
the ND1000 spectrophotometer (NanoDrop Technologies, UK). Analysis of miR-124 expression 
was carried out using the TaqMan miRNA assays (Assay ID: 001182) and performed on Applied 
Biosystems 7500 Real Time PCR system. The internal control used was RNU6B (Assay ID: 
001093). Quantitative RT-PCR analysis was performed in triplicates from four independent 
experiments. 
 
Statistical analysis  
All statistical analysis of results was carried out using the GraphPad Prism program. For 
behavioural data, and staining for NeuN, Iba-1, CD16/32, Arg-1, MBP, and miR-124, a two way 
repeated measures ANOVA was used to compare the overall effect of DHA and vehicle injection.  
Individual differences between DHA- and vehicle-treated animals were determined using Tukey’s 
post-hoc tests. For DHA-treated microglial cultures and quantitative RT-PCR analysis of miRNA, 
a one-way repeated measures ANOVA was used to compare DHA versus control groups. 
Individual differences between DHA concentrations were determined using Dunnett’s post-hoc 
tests. Statistical significance was set at p<0.05. Data points are represented as the mean +/- 
standard error of the mean (SEM). 
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For the in vitro experiments, 10 regions of each well, with each treatment and condition consisting 
of two wells were analysed. Three or four independent experiments were carried out. The number 
of cells and immunostaining intensity from the BMDM experiment was measured using the 
Thermo ScientificTM ArrayScanTM XTI High Content Analysis Reader. The statistical analysis 
used was one way ANOVA followed by Tukey’s post-hoc test. Statistical significance was set at 
p<0.05. Data points are represented as the mean +/- standard error of the mean (SEM). 
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Figure 1. DHA improves open field locomotor scores in rodent spinal cord contusion injury. 
(A) DHA-treated Sprague-Dawley rats showed significantly improved locomotor recovery when 
compared to vehicle-treated animals on days 5, 6, 7, 14, 21 and 28 post-contusion SCI when using 
the BBB locomotor rating scale. (B) DHA-treated C57BL/6 mice also showed significantly 
improved locomotor recovery when compared to vehicle-treated animals on days 11 to 35 post-
contusion SCI when using the BMS locomotor rating scale.  The i.v. dose of DHA was 500 
nmol/kg. Results are displayed as the mean ± SEM. * and ** represent p<0.05 and p<0.01 vs. 
vehicle-treated animals, respectively.  
 
Figure 2. DHA prevents NeuN immunopositive cell loss in rat and mice after contusion 
injury. (A-D) The sections rostral and caudal to the injury site of the contused rat spinal cord 
were immunostained for NeuN and analysed. Insets are enlarged images of the corresponding 
dashed boxes. (E-G) DHA-treated rats showed significantly increased NeuN immunolabelled 
cells when compared to vehicle-treated animals at 2 - 6 mm rostral to the injury site at different 
ventral and intermediate horizontal planes, at 7 days post-injury (dpi). (H-J) DHA-treated rats 
showed significantly increased NeuN immunolabelled cells when compared to vehicle-treated 
animals at 2 - 4 mm caudal to the injury site, at 28 dpi. (K-P) The sections rostral and caudal to 
the injury site of the contused mouse spinal cord were immunostained for NeuN and analysed. 
Insets are enlarged images of the corresponding dashed boxes. (Q) No difference in the number 
of NeuN immunolabelled cells was observed between DHA-treated mice and vehicle-treated 
mice in the ventral horn at 35 dpi. (R) DHA-treated mice showed significantly more NeuN 
immunolabelled cells in both caudal and rostral regions when compared to vehicle-treated 
animals at 35 dpi. (S) DHA-treated mice has significantly more neurons 3 mm rostral to the 
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injury site when both ventral horn and intermediate cord data were combined. Results are 
displayed as the mean ± SEM. * represent p<0.05 vs. vehicle-treated animals. Scale bars = 100 
m. Ventral and intermediate indicate the ventral and intermediate horizontal planes. Insets are 
enlarged images of the corresponding dashed boxes. 
 
Figure 3. DHA induces regional and temporal differences in microglia/macrophage cell 
populations after spinal cord contusion injury in rats and mice. (A-B) The 
microglia/macrophages present rostral and caudal to the injury site of the contused rat spinal cord 
were immunostained for ED1 and analysed. (C) DHA-treated animals showed significantly 
increased ED1 immunolabelled cells when compared to vehicle-treated animals at 4 mm in the 
rostral and caudal directions during the early phase (7 dpi) (p<0.05). (D-E) The 
microglia/macrophage present rostral and caudal to the injury site of the contused rat spinal cord 
were immunostained for Iba1 and analysed. Insets are enlarged images of the corresponding 
dashed boxes. (F) DHA-treated animals showed significantly increased Iba-1 immunolabelled 
cells when compared to vehicle-treated animals at the lesion epicentre and both 2-4 mm in the 
rostral and caudal directions during the early phase (7 dpi). (G) No significant difference in Iba-1 
immunolabelling was observed between DHA- and vehicle-treated animals during the late phase 
(28 dpi). (H-K) The microglia/macrophages present in gray and white matter rostral and caudal to 
the injury site of the contused mouse spinal cord were immunostained for Iba1 and analysed. Insets 
are enlarged images of the corresponding dashed boxes. Arrows indicate Iba1 immunolablled cells. 
(L) DHA-treated animals showed significantly less gray matter Iba-1 immunolabelling when 
compared to vehicle-treated animals at the injury epicentre at 35 dpi. (F) DHA-treated animals 
showed significantly greater white matter Iba-1 immunolabelling when compared to vehicle-
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treated animals, but not in any specific rostro-caudal region at 35 dpi. (G) No significant difference 
was observed when both gray and white matter data were combined. Results are displayed as the 
mean ± SEM. * represent p<0.05 vs. vehicle-treated animals. Scale bars = 100 m.  
 
 
Figure 4. DHA enhances M1 and M2 microglia/macrophage expression after spinal cord 
contusion injury in rats and mice. (A) Schematic diagram showing the rostral and caudal regions 
examined in the Western blot. (B) The expression levels of CD16/32 and (C) arginase-1 were 
upregulated after DHA compared to vehicle treatment at 3 dpi in rats. (D) III tubulin was used as 
the protein loading control. (E-F) Data expressed as mean ± SEM from 4 animals per group showed 
significant differences in CD16/32 and arginase-1 at the injury epicentre. (G-J) The M1 
microglia/macrophages immunostained for CD16/32 (arrows) showed that DHA-treated animals 
had a significant increase in CD16/32 immunolabelled cells when compared to vehicle-treated 
animals at the injury epicentre in the gray matter and 1 mm caudal in the white matter at 35 days 
post contusion. (K-N) The M2 microglia/macrophages immunostained for arginase-1 (arrows) 
demonstrated that DHA-treated animals has a significant increase in arginase-1 immunolabelled 
cells when compared to vehicle-treated animals at the injury epicentre in the gray and white matter 
and 1 mm caudal in the gray matter at 35 days post contusion. Results are displayed as the mean 
± SEM. * and ** represent p<0.05 and p<0.01 vs. vehicle-treated animals, respectively. Scale bars 
= 100 m. Insets are enlarged images of the corresponding dashed boxes. Nuclei labelled with 
DAPI are represented in blue.  
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Figure 5. DHA reduces selectively the number of murine M1 bone marrow-derived 
macrophages, but does not alter their phagocytic activity. (A-F) The bone marrow-derived 
macrophages (BMDM) can either be in a non-polarized phenotype (A-B) or be selectively 
polarized into an M1 phenotype using LPS and IFN-γ (C-D) or M2 phenotype using IL-4 (E-F). 
(G, I) For the non-polarized (M0) and M2 phenotypes, DHA (1-3 M) did not significantly alter 
the number of cells when compared to the control treatment. (H) However, for the M1 phenotype, 
DHA (3 M) significantly reduced the number of cells when compared to the control treatment. 
(J-O) BMDM immunostained for CD16/32 (green) can phagocytose DiI-labelled myelin after 24h 
co-incubation. There was no significant change in DiI-labelled myelin levels within BMDM 
treated with 3 M DHA compared to vehicle treatment at M0 (P), M1 (Q) and M2 (R) phenotypes. 
Two wells per treatment and four independent experiments were carried out. Results are displayed 
as the mean ± SEM. * represents p<0.05. Scale bars = 100 m. 
 
 
Figure 6. DHA reduces microglial phagocytosis of myelin in the white matter in rat spinal 
cord 7d after contusion. (A-L) Microglia/macrophage immunostained with Iba1 (red) and DAPI 
(blue) can phagocytose myelin (green) at 7d after spinal cord contusion. (A-F) Vehicle-or DHA-
treated animals showed high levels of phagocytosis at the epicentre level. (G-M) Vehicle-treated 
animals showed a significantly higher level of phagocytosis of myelin compared to DHA-treated 
animals at 7d after spinal contusion. Arrows illustrate high phagocytosis of myelin and arrowheads 
illustrate low phagocytosis of myelin. Results are displayed as the mean ± SEM. * and *** 
represent p<0.05 and p<0.001 vs vehicle-treated animals, respectively. Scale bars = 50 m.  
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Figure 7. DHA increases miR-124 expression in microglia in white matter in rat spinal cord 
7d after contusion. (A-F) Microglia/macrophage immunostained with Iba1 (red) and DAPI (blue) 
have a lower miR-124 expression (green) in the vehicle-treated group compared to DHA-treated 
animals. (G) A significant increase in miR-124 expression was observed at the injury epicentre 
and rostral regions along the spinal cord. Arrows indicate microglia with miR-124 expression. 
Results are displayed as the mean ± SEM. *, ** and *** represent p<0.05, p<0.01 and p<0.001, 
vs. vehicle-treated animals, respectively. Scale bars = 100 m.  
 
Figure 8. DHA reduces microglial phagocytosis of myelin via miR-124 predominantly in the 
white matter of mouse spinal cord 7d after contusion. (A) Mice receiving DHA and intraspinal 
negative control injections (blue line) showed a significantly improved locomotor activity when 
compared to animals receiving vehicle and the negative control (red line), DHA with the miR-124 
inhibitor (blue-dashed line), and vehicle with the miR-124 inhibitor (red-dashed line) when using 
the BMS locomotor rating scale, (B-K) DHA treated mice with intraspinal negative control 
injections showed significantly fewer co-localisations of MBP positive myelin (red, white arrows) 
within microglia immunostained with P2Y12 (green) compared to the other treatment groups, in 
particular, in the rostral (F) and caudal (H), but not the epicentre (G) white matter regions at or 
near contusion site. No significant change was observed in the rostral (I) and caudal (K), and 
majority of the epicentre (J) grey matter regions at or near contusion site. Results are displayed as 
the mean ± SEM. † represent p<0.05, **, ^^ and †† represent p<0.01, and ††† and ^^^ represent 
p<0.001. *, †, ^ symbols represent Vehicle with negative control, Vehicle with miR-124 inhibitor, 
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and DHA with miR-124 inhibitor compared against DHA + negative control, respectively. Scale 
bars = 100 m.  
 
 
Figure 9. DHA increases microglial miR-124 predominantly in the white matter of mouse 
spinal cord 7d after contusion. (A-C) Contused mice with vehicle and intraspinal negative 
control injections showed limited miR-124 (red, arrow heads) expression within microglia 
immunostained with P2Y12 (green, arrows) and Hoechst (blue). (D-F) However, animals 
receiving DHA treatment and intraspinal negative control injections exhibited a significant 
increase in miR-124 expression within the microglial cells. (G-L) In mice treated with the 
intraspinal miR-124 inhibitor, limited miR-124 was detected in both the vehicle- and DHA-treated 
mice. In particular, the rostral (M), epicentre (N) and caudal (O) white matter regions at or near 
the contusion site showed DHA induced miR-124, which was reduced with the miR-124 inhibitor. 
(P-R) In the grey matter regions at or near the contusion site, some specific cord regions also 
showed significant differences between the groups. Results are displayed as the mean ± SEM. *, 
**, *** represent p<0.05, p<0.01, and p<0.001 respectively. Scale bars = 100 m.  
 
Figure 10. DHA reduces microglial phagocytosis of myelin debris via miR-124 in primary 
adult microglial and microglial BV2 cell cultures. (A-F) Primary microglia from adult rat spinal 
cord immunostained with Iba1 (green) can phagocytose myelin labelled with DiI (red) after 24 h 
co-incubation. (G) DHA-treated primary microglia exhibited a significant decrease in DiI-labelled 
myelin when compared to vehicle-treated microglia at 1 µM DHA. (H-I) This significant reduction 
in phagocytosis correlated with the upregulation of miR-124, but not miR-155. Four independent 
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experiments were carried out. (J-L) BV2 microglial cells immunostained with IB4 (green) and 
Hoechst (blue) can phagocytose myelin labelled with DiI (red) after 24 h co-incubation. (M) DHA-
treated BV2 microglial cells exhibited a significant decrease in DiI-labelled myelin when 
compared to vehicle-treated microglia at 3 µM DHA. (L-M) In the presence of the miR-124 
inhibitor, the reduced microglial phagocytosis was abolished. Results are displayed as the mean ± 
SEM. * and *** represent p<0.05 and p<0.001. Scale bars = 100 m. 
 
 
Figure 11. DHA reduces microglial BV2 cell phagoptosis of UV-stressed neuronal PC12 cells. 
(A) In the absence of DHA, UV-stressed neuronal PC12 cells at the start of the experiment (0 min 
post co-incubation) express live mitochondria (stained red with TMRE) and nuclei (stained blue 
with Hoechst). Within 18 min of cell-cell contact with a microglial BV2 cell (stained green with 
CMFDA), the expression of TMRE is diminished and thereafter ‘engulfed’ by the microglial BV2 
cell by 180 min post co-incubation. (B) In the presence of DHA (3 M), even after prolonged cell-
cell contact between a UV-stressed neuronal PC12 cell and a microglial BV2 cell, the neuronal 
PC12 cells remained alive and not engulfed. (C) A significant reduction in the percentage of UV-
stressed neuronal PC12 cells was observed with microglial BV2 cells in the presence of DHA (1-
3 M). Results are displayed as the mean ± SEM. * represent p<0.05. Scale bars = 50 m. 
 
 
Suppl. Figure 1. Increased M1 and M2 expression on the ipsilateral compared to the 
contralateral side of a mouse spinal cord after 7 d post lateral hemisection. (A-C) CD16/32 
immunostaining (green), which represents the M1 phenotype was absent at rostral (A) and caudal 
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(C) levels, and limited in the ipsilateral side (indicated by *) compared to the contralateral side at 
the epicentre (B, G) region. (D-F) Arginase 1 immunostaining (green) which represents the M2 
phenotype was absent at rostral (A) and caudal (C), but a lot higher on the ipsilateral (indicated by 
*) compared to contralateral side at the epicentre (E, H) region. Results are displayed as the mean 
± SEM. Scale bars = 500 m. 
 
 
Suppl. Figure 2. Annexin V expression is increased in neuronal PC12 cell cultures after 
ultraviolet exposure. (A) Neuronal PC12 cells in the absence of UV exposure show limited 
annexin V (green) expression. (B-C) After exposure of neuronal PC12 cells to UV exposure (200 
kJ), there was a significant increase in annexin V expression. Three independent experiments were 
carried out. Results are displayed as the mean ± SEM. *** represent p<0.001. Scale bars = 50 m. 
 
 
 
 
 
 
 
 
 
 
 
52 
 
Figure 1 
 
 
53 
 
Figure 2 
 
54 
 
Figure 3 
 
 
55 
 
Figure 4 
 
 
56 
 
Figure 5 
 
57 
 
Figure 6 
 
58 
 
Figure 7 
 
59 
 
Figure 8 
 
60 
 
Figure 9 
 
61 
 
Figure 10 
 
62 
 
Figure 11 
 
63 
 
Suppl. Fig. 1 
 
64 
 
Suppl. Fig. 2 
 
 
